Bushnell Donald M, Fung Shirley, Brod Meryl, Roberts Carl A, Le Roux Carel W, Steen Oren, Lucas Kathryn J, Hennige Anita M, Uster Anastasia
PPD, Evidera, Thermo Fisher Scientific, Wilmington, North Carolina, USA.
The Brod Group, Mill Valley, California, USA.
Obesity (Silver Spring). 2025 Jul;33(7):1249-1262. doi: 10.1002/oby.24299. Epub 2025 May 28.
The objective of this study was to develop a measure of eating behaviors in adults living with obesity or overweight.
Based on concept-elicitation (n = 53) and cognitive-debriefing (n = 15) studies, a draft eating behavior patient-reported outcome (EB PRO) measure was developed. Its psychometric properties were established using data from a 46-week clinical trial of an investigational antiobesity medication (n = 387).
The final EB PRO comprised 12 items across two domains (i.e., "Desire to Eat" and "Capacity to Resist"; 6 items each) and a Total Eating Behavior score (0-48; higher scores worse). The EB PRO demonstrated good test-retest reliability (intraclass correlation coefficients > 0.7). Confirmatory factor analysis showed a comparative fit index of 0.98 with good internal consistency (Cronbach α > 0.7). The EB PRO generally exhibited moderate-to-large correlations with the Patient Global Impression of Severity questionnaire and Three-Factor Eating Questionnaire and weaker correlation with the 36-Item Short-Form Health Survey version 2 Physical Functioning scale. All EB PRO scores improved from baseline to week 46 (p < 0.0001), demonstrating sensitivity to change with therapy. Clinically meaningful thresholds were defined as eight- and four-point changes in Total Eating Behavior and domain scores, respectively.
The EB PRO measure is a promising tool for assessing eating behaviors in people with obesity or overweight.
本研究的目的是开发一种针对肥胖或超重成年人饮食行为的测量方法。
基于概念引出研究(n = 53)和认知反馈研究(n = 15),制定了一份饮食行为患者报告结局(EB PRO)测量方法草案。使用来自一种研究性抗肥胖药物的46周临床试验数据(n = 387)确定其心理测量特性。
最终的EB PRO包括两个领域的12个条目(即“进食欲望”和“抵抗能力”;各6个条目)以及一个总饮食行为得分(0 - 48;得分越高情况越差)。EB PRO显示出良好的重测信度(组内相关系数> 0.7)。验证性因素分析显示比较拟合指数为0.98,具有良好的内部一致性(Cronbach α> 0.7)。EB PRO与患者总体严重程度印象问卷和三因素饮食问卷总体呈现中度至高度相关性,与36项简短健康调查第2版身体功能量表的相关性较弱。所有EB PRO得分从基线到第46周均有所改善(p < 0.0001),表明对治疗变化具有敏感性。临床有意义的阈值分别定义为总饮食行为得分和领域得分变化8分和4分。
EB PRO测量方法是评估肥胖或超重人群饮食行为的一种有前景的工具。